基于癌症患者对自体抗原的 IgG 反应的免疫毒素-猫眼课题宝

基于癌症患者对自体抗原的 IgG 反应的免疫毒素

批准号：

9251785

负责人：

SCOTT Kendall DESSAIN

金额：

$22.53万

依托单位：

LANKENAU INSTITUTE FOR MEDICAL RESEARCH

依托单位国家：

美国

项目类别：

财政年份：

2016

资助国家：

美国

项目状态：

已结题

起止时间：

2016-04-01 至 2019-03-31

来源：

https://reporter.nih.gov/project-details/9251785

关键词：

Address Affinity Alpha Cell Amino Acids Antibodies Antibody Response Antibody-drug conjugates Antigen Targeting Antigens Aspergillus Autoantigens B lymphocyte immortalization B-Lymphocytes Bacterial Toxins Binding Biodistribution Cancer Etiology Cancer Patient Cancer cell line Cell Line Cell hybridization Cell surface Cells Cessation of life Characteristics Clinical Cloning Colon Carcinoma Computer Simulation Dose Drug Kinetics GPA33 gene Generations Human Hybrid Cells Immune system Immunoglobulin G Immunoprecipitation Immunotoxins In Vitro Malignant Neoplasms Malignant neoplasm of lung Measures Methods Modeling Molds Monoclonal Antibodies Mus Mutate Mycotoxins Neoplasm Metastasis Non-Small-Cell Lung Carcinoma Normal Cell Patients Performance Personal Communication Phenotype Process Protein Isoforms Proteins RNA Splicing Recombinants Research Safety Solid Neoplasm Specificity Structure T-Lymphocyte T-Lymphocyte Epitopes Testing Therapeutic Toxic effect Toxin Trastuzumab Tumor Antigens United States Xenograft Model Xenograft procedure base bevacizumab cDNA Library cancer cell cancer immunotherapy cancer stem cell cancer therapy cell killing chimeric antigen receptor clinical development cytotoxic efficacy testing experimental study glycosylation human monoclonal antibodies immunogenicity in vitro activity in vitro testing in vivo killings lymph nodes malignant breast neoplasm mouse model novel overexpression public health relevance response screening success tumor tumorigenesis

项目摘要

项目成果

SCOTT Kendall DESSAIN的其他基金

相似基金

相关文献

中文摘要

翻译

描述(申请人提供)：肺癌是美国癌症死亡的主要原因，但由于缺乏针对肺癌细胞的已知抗体靶点，基于单抗(MAbbs)的治疗前景尚未实现。这项研究将通过鉴定三种新的肺癌特异性单抗来满足这一需求，这些单抗是从癌症患者中克隆的，当转化为抗体药物结合物时，在体外显示出细胞毒活性。我们将把它们转化为免疫毒素，测试并确定它们对肺癌的特异性、安全性和有效性。

英文摘要

DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer death in the United States, but the promise of therapies based on monoclonal antibodies (mAbs) has been unrealized due to the lack of known antibody targets specific for lung cancer cells. This research will address this need by characterizing three new lung cancer-specific mAbs that were cloned from patients with cancer and have shown cytotoxic activity in vitro when converted into antibody drug conjugates. We will convert them into immunotoxins and test them for and determine their specificity, safety and efficacy against lung cancer.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文